ClinicalTrials.gg
RecruitingNCT06254326ADAGiOUpdated Nov 17, 2026

ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients

A Phase 1 interventional study of TTRNA-DC vaccines with GM-CSF and Autologous Hematopoietic Stem cells (HSCs) in Recurrent Oligodendroglioma and Progressive Oligodendroglioma, sponsored by University of Florida. Recruiting at 1 site in United States. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by University of Florida · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.
Updated Nov 17, 2026Now RecruitingNow Active, not recruiting+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 339 studies in Oligodendroglioma with a site in United States — 19 open to participants now, 35 under way, 4 of them phase 3. Oligodendroglioma · United States.

Planned enrollment
215th of 273
12 · median 30
Started
2024
with 4 others
Phase 1
148 of 339
4 open now
Primary completion
2027-12
later than 18 of 34 live
Registered
327th of 339
by date

Among the 339 studies in Oligodendroglioma with a site in United States, this one is the 215th largest by planned enrollment of the 273 interventional ones that give a count, is one of 5 that started in 2024, is one of 148 in phase 1, reaches primary completion later than 18 of the 34 other live ones, and was the 327th registered.

Oligodendroglioma

414 studies on the registry are indexed under Oligodendroglioma; 33 are open to participants now.

Browse Oligodendroglioma studies →

Open to participants now

19 of the 339 studies in Oligodendroglioma with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 26 Oligodendroglioma studies recruiting now, 16 (62%) set no upper age limit and 7 (27%) stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 89 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 339 studies in Oligodendroglioma with a site in United States, or all of them as a file.
02

Study summary

This study will enroll 6 DLT evaluable subjects (up to 12 patients total) where we will evaluate feasibility and safety of adoptive cellular therapy combined with IDH1/2 inhibitors in patients with recurrent or progressive oligodendroglioma WHO grade 2 and WHO grade 3.

Read the detailed description

After screening consent, subjects will undergo standard of care resection or biopsy for confirmatory diagnosis of disease progression and aseptic collection of tumor material for DNA and RNA extraction and sequencing, amplification, and loading of autologous DCs. Following biopsy and confirmatory pathologic diagnosis, eligible patients will be enrolled in treatment.

After surgery, patients will undergo a G-CSF mobilized pheresis to collect PBMCs for DC generation and CD34+ HSCs. Amplified tumor RNA obtained from surgically resected or biopsied specimens will be used to generate total tumor RNA-pulsed DCs (TTRNA-DCs) manufactured while patients initiate salvage chemotherapy regimen after surgery.

Salvage chemotherapy with IDH1/2 inhibitor will initiate 1-2 weeks after G-CSF mobilized leukapheresis for 1-3 cycles after which, treatment cycles will be paused, and the patients will receive 3 priming TTRNA-DCs vaccines every 2 weeks and undergo a non-mobilized leukapheresis to collect vaccine-boosted lymphocytes for ex vivo T cell expansion and generation of additional TTRNA-DC vaccines. Treatment with IDH1/2 inhibitor will resume with monthly TTRNA-DC vaccines for an additional 1-3 cycles until ex vivo expanded T cells are manufactured.

For ACT, patients will undergo non-myeloablative conditioning with cyclophosphamide /fludarabine. The total immunotherapy regimen will consist of up to 9 intradermal DC vaccines (three -bi-weekly (q2 weeks) for priming, monthly for additional 2-3 cycles during T cell expansion, and three bi-weekly during T cell engraftment), a single i.v. infusion of ex vivo expanded tumor-reactive T cells, and a i.v. single infusion of autologous HSCs.

The duration of treatment from enrollment to completion of DLT window is anticipated to be 7 to 9 months.

03

Conditions studied

  • Recurrent Oligodendroglioma
  • Progressive Oligodendroglioma

Keywords

  • Immunotherapy
  • Brain Tumor
04

Who can participate

The criteria were revised on the registry on Nov 13, 2026. See what changed

Ages eligible
18 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged 18 years and above
  • Tumor tissue obtained on a screening consent is available.
  • Confirmed with recurrent/progressive IDH-mutant 1p/19q co-deleted Oligodendroglioma WHO grade 2 or WHO grade 3 (Patients who received prior radiation must be more than 12 weeks from completion of radiation).
  • Performance Status ≥ 60
  • Must be a candidate for surgery/
  • Adequate bone marrow and organ function as defined below:

    • ≥ 1,000/mcL
    • ≥ 100,000/mcL
    • ≥ 9 g/dL (can be transfused)
    • Serum creatinine ≤ 1.5 x IULN OR by Cockcroft-Gault ≥ 60 mL/min for patients with serum creatinine > 1.5 x IULN
    • Serum total ≤ 1.5 x IULN OR Direct bilirubin ≤ IULN for patients with total bilirubin > 1.5 x IULN
    • (SGOT) and ALT (SGPT) ≤ 3 x IULN
  • For females of , negative serum pregnancy test at enrollment
  • For women and men of childbearing potential (WOCBP) must be willing to use acceptable methods

Exclusion criteria

Exclusion Criteria:

  • Prior invasive (except for non-melanomatous skin cancer) unless disease free for ≥ 3 years.
  • detected below the tentorium or beyond the cranial vault and .
  • Multifocal disease, defined as more than one enhancing lesion separated by noncontiguous T2/FLAIR signal abnormality, as determined by the PI. This exclusion does not apply to patients presenting with a new, separate lesion outside the original tumor site at recurrence, provided the original site of disease remains stable, as determined by the PI.
  • equivalent to ≥ 4mg dexamethasone daily.
  • , , or seropositive.
  • Known active infection or disease.
  • disease requiring medical management with immunosuppressant.
  • Pregnancy or lactation, due to possible adverse effects on the developing fetus or infant.
  • Treatment with another drug or other intervention within 30 days prior to projected first dose of study treatment (Priming phase with TTRNA-DC).
  • Severe, active co-morbidity, defined as follows:

    • Unstable angina and/or congestive heart failure requiring hospitalization.
    • Transmural myocardial infarction within the last 6 months.
    • Acute bacterial or fungal infection requiring intravenous antibiotics at time of enrollment.
    • exacerbation or other respiratory illness requiring hospitalization or precluding study therapy.
    • Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects.
    • Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive.
    • Major medical illnesses or psychiatric impairments that, in the investigator's opinion, will prevent administration or completion of protocol therapy.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Adoptive Cellular Therapy

    All participants will receive 9 intradermal DC vaccines (three -bi-weekly (q2 weeks) for priming, monthly for additional 2-3 cycles during T cell expansion, and three bi-weekly during T cell engraftment), a single i.v. infusion of ex vivo expanded tumor-reactive T cells, and a i.v. single infusion of autologous HSCs.

    Biological: TTRNA-DC vaccines with GM-CSF · Biological: Autologous Hematopoietic Stem cells (HSCs) · Biological: TTRNA-xALT · Drug: Td vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Prevalence of enrolled subject who receive qualified immunotherapy investigational product.

    Feasibility will be measured by the number of patients who receive autologous dendritic cells, T cells and hematopoietic stem cells that meet the FDA IND defined quality assurance and quality control release criteria. A minimum of 66.7% of enrolled subject must achieve this criterion for feasibility endpoint.

    Time frame: enrollment up to 9 months

  2. Incidence of investigational treatment related severe toxicity (Dose-limiting toxicity event) assessed during the period beginning with administration of ex vivo expanded TTRNA T cells through 6 weeks post infusion.

    Safety will be defined as \< 1 DLT out of six enrolled and treated subjects during the defined period of administration of ex vivo expanded TTRNA T cells through 6 weeks post infusion. Investigational treatment related CTCAE V5.0 adverse events 1) Grade III or greater non-neurologic toxicity; 2) Grade III neurologic toxicity that does not improve to Grade II or better within 5 days; or 3) Grade IV neurologic toxicity will be recorded toward DLT.

    Time frame: enrollment to completion of DLT window; up to 9 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Dec 2027, 39 months after the start.

Of 36 non-industry phase 1 interventional studies under Oligodendroglioma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 92. This study's planned 39 months is below that.

Counting every sponsor, half of 43 studies reached it within 44 months; a quarter within 35 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2024
First posted
Feb 12, 2024
StartActual
Sep 19, 2024
Primary completionEst.
Dec 2027
CompletionEst.
Jun 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting→Recruiting
changed Nov 2, 2026 · changed Nov 17, 2026
Sites
University of Florida Health Shands Hospital is now Recruiting
Nov 17, 2026
Eligibility
1 inclusion criterion edited; 1 exclusion criterion added, 2 removed
What changed in the criteria
Inclusion criteria
  • EditedConfirmed with recurrent/progressive IDH-mutant 1p/19q co-deleted Oligodendroglioma WHO grade 2 or WHO grade 3, (Patients who received prior radiation must be more than 12 weeks from completion of radiation).
Exclusion criteria
  • RemovedDisease progression during treatment with an anti-IDH-1 or anti IDH-2
  • RemovedMultifocal disease.
  • AddedMultifocal disease, defined as more than one enhancing lesion separated by noncontiguous T2/FLAIR signal abnormality, as determined by the PI. This exclusion does not apply to patients presenting with a new, separate lesion outside the original tumor site at recurrence, provided the original site of disease remains stable, as determined by the PI.
Nov 13, 2026
Contact
Study contact now listed: added p•••@neurosurgery.ufl.edu · •••9000. See the current contact
Nov 17, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • University of Florida Health Shands Hospital · Gainesville, United StatesContact added (no phone or email listed)Contact added p•••@neurosurgery.ufl.edu · •••9000Contact added (no phone or email listed)
Nov 17, 2026
Show all 4 updates
  1. Nov 17, 2026
    Active, not recruiting→Recruiting
    University of Florida Health Shands Hospital is now Recruiting
    Contact Study contact now listed: added p•••@neurosurgery.ufl.edu · •••9000. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of Florida Health Shands Hospital · Gainesville, United StatesContact added (no phone or email listed)Contact added p•••@neurosurgery.ufl.edu · •••9000Contact added (no phone or email listed)
  2. Nov 13, 2026
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion added, 2 removed
    What changed in the criteria
    Inclusion criteria
    • EditedConfirmed with recurrent/progressive IDH-mutant 1p/19q co-deleted Oligodendroglioma WHO grade 2 or WHO grade 3, (Patients who received prior radiation must be more than 12 weeks from completion of radiation).
    Exclusion criteria
    • RemovedDisease progression during treatment with an anti-IDH-1 or anti IDH-2
    • RemovedMultifocal disease.
    • AddedMultifocal disease, defined as more than one enhancing lesion separated by noncontiguous T2/FLAIR signal abnormality, as determined by the PI. This exclusion does not apply to patients presenting with a new, separate lesion outside the original tumor site at recurrence, provided the original site of disease remains stable, as determined by the PI.
    + 1 other change: verification date
  3. Nov 2, 2026
    Recruiting→Active, not recruiting
    + 2 other changes: contact details and site details
  4. Oct 30, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06254326
Collaborators
Oligo Nation, Inc
Responsible party
Sponsor
First posted
Feb 12, 2024
Start date
Sep 19, 2024
Primary completion
Dec 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Phuong Deleyrolle, RN
Contact
phuong.deleyrolle@neurosurgery.ufl.edu
352-273-9000
Duane Mitchell, MD, PhD
study chair · University of Florida
Ashley Ghiaseddin, MD
principal investigator · University of Florida

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Total Tumor mRNA-pulsed Tumor-specific Ex vivo-expanded Autologous Lymphocyte Transfer Cells · Diphtheria-Tetanus Vaccine

Start the discussion